Basic Information
Trelegy Ellipta
Regulatory Information
EMEA/H/C/004363
November 15, 2017
September 14, 2017
12
May 5, 2025
Company Information
Ireland
12 Riverwalk Citywest Business Campus Dublin 24
GLAXOSMITHKLINE SOUTH AFRICA (PTY) LTD
Active Substances Detail
fluticasone furoateumeclidinium bromidevilanterol trifenatate
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting ?2-agonist.
Overview Summary
Trelegy Ellipta is a medicine used to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Trelegy Ellipta is used in adults whose disease is not controlled well enough with a combination of inhaled medicines consisting of a long-acting beta-2 agonist plus either a corticosteroid or a long-acting muscarinic antagonist. Long-acting beta-2 agonists widen the airways; corticosteroids reduce inflammation in the airways and lungs; and muscarinic receptor antagonists cause the muscles of the airways to relax. Trelegy Ellipta is used for maintenance (regular) treatment on a daily basis. It contains the active substances fluticasone furoate, umeclidinium bromide and vilanterol.